Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 1149

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 14
Chunk 1149
---

NOTE 9 — SUBSEQUENT EVENTS 

The Company evaluated subsequent events and transactions
that occurred after the balance sheet and through the date that the financial statement was issued. Based upon this review, other than
as noted below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statement.

On January 29, 2025, the Company repaid the Sponsor
$900,000 simultaneously with the closing of the Initial Public Offering.

On January 29, 2025, the Company has entered into
an amended and restated private units purchase agreement with the Sponsor, pursuant which the Sponsor agreed to purchase an aggregate
of 400,000 Private Placement Units (or 430,000 Private Placement Units if the underwriters’ over-allotment is exercised in full)
at a price of $10.00 per Private Placement Unit ($4,000,000, or an aggregate of $4,300,000 if the underwriters’ over-allotment is
exercised in full) from the Company in the Private Placement. Under the agreement, the Company issued a new unsecured subscription promissory
note to the Sponsor (the “Subscription Promissory Note”) to which the Company may borrow up to $1,100,000 in working capital
loans under the Subscription Promissory Note, which loans shall be converted into Private Placement Units, at the price of $10.00 per
unit. To the extent the amount of such loans is less than $1,100,000, the Sponsor agreed that it (or, if applicable, it and any transferees
of Private Placement Units) shall surrender for cancellation any and all rights to up to an aggregate of 110,000 Private Placement Units
at $10.00 per unit (see Note 4 and Note 5).

On January 29, 2025, the Company consummated the
Initial Public Offering of 20,000,000 Units at $10.00 per Unit, generating proceeds of $200,000,000, which is described in Note 1 and
Note 3.

Simultaneously with the closing of the Initial
Public Offering, the Company consummated the sale of 400,000 Private Placement Units at a price of $10.00 per Private Placement Unit in
a private placement to the Sponsor, for $4,000,000, of which $1,100,000 has not yet been received and